Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2023. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share transactions executed on the New York Stock Exchange (XNYS).
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W2044
- Transaction Date: January 30, 2023
- Transaction Price: $35.5198 per ADS
- Total Volume Reported: 1,746.964 ADSs (across three individuals)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine acquisitions of ADSs by three executives following the re-investment of dividends paid to shareholders on January 12, 2023.
Management Commentary and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a statutory disclosure of specific share purchases.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ADSs via dividend re-investment, not open market purchases or sales.
- Participants:
- Dr. H. Barron (Non-Executive Director): Acquired 1,421.208 ADSs.
- Mr. J. Ford (SVP and Group General Counsel): Acquired 276.356 ADSs.
- Shobie Ramakrishnan (Chief Digital and Technology Officer): Acquired 49.400 ADSs.
- Valuation: The transactions occurred at a uniform price of $35.5198 per ADS.
- Scope: This filing does not contain financial performance data for GSK plc; investors should refer to Form 20-F or quarterly earnings releases for financial metrics.